Shares of Valeant Pharmaceuticals International surged more than 25 percent on Tuesday, to close at $28.16, after the reeling drug maker maintained its guidance for the year when it announced quarterly earnings. It also unveiled a restructuring of its businesses. “We are also announcing a new strategic direction for Valeant
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.